XML 41 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Consolidated Statements of Operations (Unaudited) (USD $)
 3 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Revenues:    
Revenue under collaborative research and development arrangements $ 1,435,727 $ 14,259
Revenue under collaborative research and development arrangements with affiliated entity 116,964 106,250
Grants and miscellaneous revenue 804,952 1,334,716
Total revenues 2,357,643 1,455,225
Operating expenses:    
Research and development 8,225,480 5,115,112
General and administrative 4,132,218 2,974,153
Total operating expenses 12,357,698 8,089,265
Loss from operations (10,000,055) (6,634,040)
Other income (expense):    
Interest and other income, net 52,076 39,460
Change in fair value of common stock warrants (505,926) (1,427,616)
Loss on investment in affiliated entity (376,963) (836,084)
Net loss (10,830,868) (8,858,280)
Net loss attributable to non-controlling interest 9,408 14,160
Net loss attributable to Inovio Pharmaceuticals, Inc. $ (10,821,460) $ (8,844,120)
Loss per common share—basic and diluted:    
Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders (in USD per share) $ (0.05) $ (0.06)
Weighted average number of common shares outstanding—basic and diluted (in shares) 220,636,004 156,155,532